Le Lézard
Classified in: Health
Subjects: PDT, FDA

BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System

FRANKLIN LAKES, N.J., July 19, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD FACSLyrictm flow cytometer system, an easy-to-use in vitro diagnostic (IVD) system, for use with BD Multitesttm assays for immunological assessment of individuals and patients having or suspected of having immune deficiency.

BD FACSLyricTM Flow Cytometer System

The BD FACSLyric system strengthens BD's portfolio of clinical flow cytometry solutions available in the U.S. The system was CE marked to the EU IVD Directive last year.

The new flow cytometer system combines a benchtop-sized instrument with software, reagents and services to provide clinicians and scientists with accurate, reliable and repeatable results.

"The FDA clearance of the BD FACSLyric system continues BD's drive to increase access to new innovations in clinical flow cytometry technology to more labs around the world," said John Ledek, president of Biosciences for BD. "BD recognizes that products for the clinical market require ease of use and standardization from instrument to instrument to ensure consistent results that ultimately inform patient care."

BD FACSLyric supports the BD Multitesttm 4-Color assays and the BD Multitesttm 6-Color TBNK assay, which are some of the most used flow-based IVD assays. These tests determine the percentages and absolute counts of T, B and natural killer (NK) cells, as well as the CD4 and CD8 subsets of T cells. Together, these metrics can be used in the immunological assessment of individuals and patients having, or suspected of having, immune deficiency. The BD FACSLyric cell analyzer is available in four configurations to provide laboratories with the flexibility to adapt to changing clinical needs. More IVD assays will be added to the BD FACSLyric solution as they become available.

The BD FACSLyric system is available as an IVD instrument in the U.S., Europe and other geographies. For more information, visit bdbiosciences.com.

About BD
BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has nearly 50,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. For more information on BD, please visit bd.com.


Gwen Gordon   

Monique N. Dolecki

BD Public Relations

BD Investor Relations






SOURCE BD (Becton, Dickinson and Company)

These press releases may also interest you

at 09:01
While the ability of grape seed extract's oligomeric proanthocyanidins (OPC) to prevent tumors has been previously demonstrated, the underlying mechanisms have not been fully explored. A recent study, published in the journal Scientific Reports, has...

at 09:00
Processa Pharmaceuticals, Inc. announced today that, as agreed in the asset purchase of Promet Therapeutics, LLC, Processa has been assigned the license for CTP-499 upon Promet's exercising of the exclusive option to license in CTP-499 from Concert...

at 09:00
CVS Health today announced two initiatives in New Hampshire to combat opioid abuse.  The company has installed safe medication disposal units inside two CVS Pharmacy locations in New Hampshire to help facilitate proper and timely disposal of opioids...

at 09:00
AbbVie , a research and development-based global biopharmaceutical company, and the International Myeloma Foundation (IMF) today announced they have entered into a collaboration to conduct a landmark retrospective chart review study to better...

at 09:00
FN Media Group Presents USA News Group News Commentary  USA News Group - As evidence to the shift in public perception of marijuana use, the Province of Ontario has announced plans to legalize Cannabis lounges once the country's Cannabis Act is...

at 09:00
Collagen Matrix, Inc., a leader in regenerative medicine and a global manufacturer of collagen and mineral based medical devices, announced today the appointment of Gregory Pomrink as Vice President, Research and Development to further leverage its...

News published on 19 july 2017 at 06:59 and distributed by: